What is the recommended treatment for an acute pseudogout (calcium pyrophosphate crystal arthritis) attack?

Treatment of Acute Pseudogout (Calcium Pyrophosphate Crystal Arthritis)

For acute pseudogout attacks, start with joint aspiration followed by intra-articular corticosteroid injection for monoarticular or oligoarticular disease—this approach alone is often sufficient and carries the highest strength of recommendation (95% SOR) from EULAR guidelines. 1

First-Line Treatment Algorithm

For Monoarticular or Oligoarticular Attacks:

1. Joint aspiration (confirms diagnosis, excludes septic arthritis, provides symptomatic relief)
2. Intra-articular long-acting corticosteroid injection immediately after aspiration
3. Ice/cool packs and temporary rest of the affected joint

This combination has a 95% strength of recommendation and for many patients requires no additional systemic therapy 1.

For Polyarticular Attacks or When Intra-articular Injection Not Feasible:

Systemic corticosteroids are the preferred option:

• Intramuscular betamethasone 7 mg (single injection), OR
• Intravenous methylprednisolone 125 mg (single injection), OR
• Short tapering course of oral corticosteroids
• Parenteral ACTH 40-80 units (IM/IV/SC, given three times) is an alternative

Evidence shows systemic corticosteroids achieve faster pain control than NSAIDs (NNT=3 on day 1) and are particularly valuable in elderly patients with contraindications to NSAIDs 1.

Second-Line Systemic Options

When corticosteroids are contraindicated or insufficient:

NSAIDs:

• Always prescribe with gastroprotection (proton pump inhibitor)
• Standard dosing for acute inflammation
• Major caveat: High risk of GI bleeding, cardiovascular events, and renal impairment, especially in elderly patients who comprise the majority of pseudogout cases 1

Colchicine:

• Low-dose regimen: 0.5 mg three to four times daily (with or without 1 mg loading dose)
• Avoid traditional high-dose regimens (1 mg loading, then 0.5 mg every 2 hours)—these cause 100% incidence of side effects 1
• Major caveat: Diarrhea is common; use cautiously in elderly patients with renal impairment and multiple comorbidities 1
• Never use intravenous colchicine—high risk of serious toxicity and fatality 1

Critical Clinical Considerations

Age and comorbidity drive treatment selection. Pseudogout predominantly affects older patients with chronic renal impairment and multiple comorbidities, making NSAIDs and colchicine particularly hazardous 1. This is why intra-articular corticosteroids receive the highest recommendation—they avoid systemic toxicity.

Evidence quality is limited. Most treatment recommendations are extrapolated from gout studies (Level Ib-IV evidence). No RCTs exist specifically for NSAIDs or intra-articular corticosteroids in pseudogout 1, 2. The strongest evidence supports systemic corticosteroids showing faster symptom control than NSAIDs in crystal arthritis 1.

Common Pitfalls to Avoid

• Don't use traditional high-dose colchicine regimens—they guarantee side effects without added benefit
• Don't prescribe NSAIDs without gastroprotection in this elderly population
• Don't forget to aspirate the joint first—this confirms diagnosis, excludes septic arthritis (a critical differential), and provides therapeutic benefit
• Don't use intravenous colchicine—it's no longer recommended due to toxicity risk 1

Treatment Hierarchy Based on Joint Involvement

Monoarticular/Oligoarticular:

1. Joint aspiration + intra-articular corticosteroid (first choice)
2. Systemic corticosteroids (if injection not feasible)
3. NSAIDs with gastroprotection OR low-dose colchicine (if corticosteroids contraindicated)

Polyarticular:

1. Systemic corticosteroids (oral taper, IM/IV injection, or ACTH)
2. NSAIDs with gastroprotection OR low-dose colchicine
3. Combination therapy if monotherapy insufficient

The treatment must be individualized based on the number of joints involved, patient age, renal function, cardiovascular risk, and GI risk factors 1. However, the algorithmic approach above provides the evidence-based hierarchy for decision-making, with intra-articular corticosteroids as the gold standard for localized disease and systemic corticosteroids for widespread attacks.